CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

NCT06079983 · Phase 3 · Recruiting

PHASEPhase 3

STATUSRecruiting

ENROLLMENT400

EST. COMPLETION2026-04-01

Conditions

Breast Cancer

Interventions

JSKN003Capecitabine tabletsGemcitabine hydrochloride for injectionVinorelbine tartrate injectionPaclitaxel for injection (albumin-bound type)Docetaxel injectionEribulin mesylate injection

Study details

SPONSORJiangsu Alphamab Biopharmaceuticals Co., Ltd

START DATE2023-12-01

Related company profiles

Alphamab Oncology

9966.HK

Primary source

ClinicalTrials.gov record NCT06079983 ↗

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier: NCT06079983
Event / action date: Not separately retained
Source update date: Not separately retained
Platform retrieval / processing date: Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record